VibraCool Device to Reduce Pain and Opioid Use After Anterior Cruciate Ligament Reconstruction (ACLR)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorColumbia University

About this trial

The goal of this project is to test the effects of the VibraCool mechanical stimulation neuromodulatory therapeutic device on post-operative pain and opioid use following anterior crucitate ligament reconstruction (ACLR), and thus residual opioids in circulation.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Underwent ACL reconstruction

Disqualifiers

Pediatric iliotibial band ACL reconstruction (known to cause significantly more pain)

Non-english speakers (limitations of our study group)

Trial design

Design model

Parallel

Treatments tested in this trial

  • VibraCool mechanical stimulation and neuromodulatory therapeutic device

    Device

    Multiple studies have shown that vibration sources applied to muscles prior to exercise reduced soreness and lactate dehydrogenase production, and increased range of motion at 48 and 72 hours. Acute pain results from fast A nerves transmitting nociceptive information to the dorsal column, where the substantia gelatinosa's interneurons prioritize competing A mechanoreceptor and C-fibers to slow pain transmission. One study observed that stimulation of A mechanoreceptors "shut the gate" on pain transmission, an inhibitory mechanism known as "gate control". Multiple physical methodologies leverage gate control physiology for pain relief, such as vibratory massage therapy and electrical stimulation to varying degrees. However, the use of vibratory massage to improve pain control and reduce opioid use following ACLR has not been well studied, and to our knowledge there are no randomized control trials (RCTs) evaluating the use of this modality compared to standard ice or cryocompression.

  • Cryocompression (Game Ready, Bregs) device

    Device

    Cryotherapy has also been used as an adjunctive post-operative therapy to reduce pain and inflammation following anterior cruciate ligament reconstruction (ACLR). It has been shown to decrease local metabolism, resulting in reduced pain and inflammation. Multiple studies have shown the benefits of using cryotherapy after ACLR, and more recently dynamic intermittent compression has been shown to improve circulation while reducing the risk of skin necrosis associated with static permanent compression. A recent meta-analysis including ten RCTs found significant reductions in post-operative VAS pain scores and breakthrough opioid consumption when using cryotherapy, such as Game Ready or Breggs ice therapy, following ACLR.

  • Standard ice packs

    Device

    Cold also provides peripheral gate-control relief via small, slow C-Fibers that transmit low level pain. In addition to local pain relief, intense cold can raise the A pain threshold distant to the location. The mechanism has been called descending or diffuse noxious inhibitory relief, or more recently conditioned pain modulation (CPM). Injections, aches, and infiltration of local anesthesia and dermal fillers are relieved by applying cold. For acute injury, near freezing cold relieves pain by suppressing the local metabolic production of inflammation and concomitant tissue ischemia from hypoxia due to the increased metabolic rate.

Treatment groups

130 Participants
are divided into 3 treatment groups
Group A: Standard Ice packsActive comparator 1 intervention
Group B: Cryocompression deviceActive comparator 1 intervention
Group C: VibraCoolExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Visual Analog Score (VAS) for pain

Scale of 0 to 10, with 10 being the worst pain and 0 being no pain. Will record daily mean VAS pain scores over the first seven post-operative days

Time frame
First 7 post-operative days
2

Opioid use

Percent of patients discontinuing opioid use by or on post-operative day three, compared to those who continue after day three

Time frame
First 3 post-operative days

Secondary outcomes

1

Mean reduction in opioid use in mg of morphine equivalents per day

mean reduction in opioid use in milligrams of morphine equivalents per day (MMOD) of 30% from patients not using the device over the 7-day period

Time frame
First 7 post-operative days
2

Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference score

PROMIS is a computerized adaptive patient-reported test to measure interference of pain in everyday functioning. The raw score is converted to a T-score metric in which 50 is the mean and 10 is the standard deviation. Higher T-scores represent increased pain interference.

Time frame
First 7 post-operative days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.